We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+4.73%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$270M
AUM Growth
-$29.4M
Cap. Flow
-$45.9M
Cap. Flow %
-17.01%
Top 10 Hldgs %
39.46%
Holding
110
New
22
Increased
25
Reduced
44
Closed
14

Top Buys

Rank Stock Value
1
AMSG
Amsurg Corp
AMSG
+$10.3M
2
ESRX
Express Scripts Holding Company
ESRX
+$3.67M
3
AKRX
Akorn Inc
AKRX
+$3.38M
4
SHPG
Shire pic
SHPG
+$3.35M
5
HCA icon
HCA Healthcare
HCA
+$3.33M

Top Sells

Rank Stock Value
1
WMGI
Wright Medical Group Inc
WMGI
+$8.81M
2
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$8.25M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$5.07M
4
EHC icon
Encompass Health
EHC
+$5.04M
5
BDX icon
Becton Dickinson
BDX
+$4.8M

Sector Composition

Rank Sector Weight
1 Healthcare 87.33%
2 Financials 3.58%
3 Industrials 1.13%
4 Energy 0.58%
5 Technology 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
76
Vertex Pharmaceuticals
VRTX
$121B
$449K 0.17%
5,150
-1,100
-18% -$104K
LUMO
77
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$447K 0.17%
3,310
-3,633
-52% -$361K
BAX icon
78
Baxter International
BAX
$13.5B
$396K 0.15%
8,309
-11,600
-58% -$547K
TRIL
79
DELISTED
Trillium Therapeutics Inc.
TRIL
$361K 0.13%
24,400
-2,900
-11% -$33.4K
PCRX icon
80
Pacira BioSciences
PCRX
$1.04B
$359K 0.13%
10,500
– –
ONCE
81
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$348K 0.13%
+5,800
New +$334K
BDX icon
82
Becton Dickinson
BDX
$45.6B
$341K 0.13%
1,948
-28,042
-94% -$4.8M
RDUS
83
DELISTED
Radius Health, Inc.
RDUS
$341K 0.13%
6,300
-1,900
-23% -$96.6K
TSRO
84
DELISTED
TESARO, Inc.
TSRO
$341K 0.13%
+3,400
New +$318K
RXDX
85
DELISTED
Ignyta, Inc.
RXDX
$328K 0.12%
52,200
+32,000
+158% +$186K
MRK icon
86
Merck
MRK
$322B
$318K 0.12%
+5,345
New +$313K
FOLD
87
DELISTED
Amicus Therapeutics
FOLD
$317K 0.12%
+42,900
New +$290K
RIGL icon
88
Rigel Pharmaceuticals
RIGL
$681M
$310K 0.11%
+8,444
New +$242K
ANIP icon
89
ANI Pharmaceuticals
ANIP
$1.8B
$305K 0.11%
+4,600
New +$288K
CLVS
90
DELISTED
Clovis Oncology, Inc.
CLVS
$299K 0.11%
+8,300
New +$178K
OCRX
91
DELISTED
Ocera Therapeutics, Inc.
OCRX
$272K 0.1%
103,142
– –
CHRS icon
92
Coherus Oncology
CHRS
$217M
$225K 0.08%
+8,400
New +$229K
RGNX icon
93
Regenxbio
RGNX
$620M
$168K 0.06%
+12,026
New +$133K
RAD
94
DELISTED
Rite Aid Corporation
RAD
$136K 0.05%
885
-2,145
-71% -$320K
ARRY
95
DELISTED
Array Biopharma Inc
ARRY
$68K 0.03%
+10,000
New +$38.7K
AMPH icon
96
Amphastar Pharmaceuticals
AMPH
$879M
– –
-48,825
Closed -$787K
HUM icon
97
Humana
HUM
$43.7B
– –
-1,798
Closed -$323K
LAB icon
98
Standard BioTools
LAB
$340M
– –
-256,490
Closed -$2.32M
MD icon
99
Pediatrix Medical
MD
$2.18B
– –
-17,000
Closed -$1.23M
MTD icon
100
Mettler-Toledo International
MTD
$28.6B
– –
-1,100
Closed -$401K
1 2 3
4
5

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, Endurant Capital Management held 110 positions worth $270M, down 9.8% from $299M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Endurant Capital Management withdrew a net $45.9M in Q3 2016, closing 14 positions and reducing 44 holdings. Its most notable exit was Standard BioTools, an estimated $2.32M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 89% a quarter earlier, followed by Financials and Industrials.

Against the trend, Endurant Capital Management opened a new position in Amsurg Corp worth $9.89M.

  • Endurant Capital Management's largest Q3 2016 buy was Amsurg Corp: 147,500 shares worth $9.89M.
  • Endurant Capital Management added most to Express Scripts Holding Company in Q3 2016, an estimated $3.67M increase.
  • Endurant Capital Management's biggest Q3 2016 reduction was Wright Medical Group Inc, cutting an estimated $8.81M.
  • Endurant Capital Management fully exited Standard BioTools in Q3 2016, selling an estimated $2.32M.
  • Endurant Capital Management's ten largest holdings make up 39% of its $270M portfolio in Q3 2016.
  • Endurant Capital Management opened 22 new positions and closed 14 in Q3 2016.
  • Endurant Capital Management's portfolio value fell 9.8% quarter-over-quarter to $270M.

Based on Endurant Capital Management's 13F filing for Q3 2016, filed 15 Nov 2016.